腺病毒载体疫苗的快速响应制造。 - Suppr | 超能文献

相似文献

1

Rapid-response manufacturing of adenovirus-vectored vaccines.腺病毒载体疫苗的快速响应制造。

Nat Biotechnol. 2023 Mar;41(3):314-316. doi: 10.1038/s41587-023-01682-2.

2

Use of adenovirus type-5 vectored vaccines: a cautionary tale.5型腺病毒载体疫苗的使用：一个警示故事。

Lancet. 2020 Oct 31;396(10260):e68-e69. doi: 10.1016/S0140-6736(20)32156-5. Epub 2020 Oct 19.

3

Adenovirus-based expression vectors and recombinant vaccines.基于腺病毒的表达载体和重组疫苗。

Biotechnology. 1992;20:363-90. doi: 10.1016/b978-0-7506-9265-6.50022-1.

4

Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials.大规模腺病毒和痘病毒载体疫苗生产以支持临床试验。

Biotechnol J. 2015 May;10(5):741-7. doi: 10.1002/biot.201400390. Epub 2015 Apr 24.

5

Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines.腺病毒载体和痘病毒载体结核病疫苗研发的最新进展。

Curr Gene Ther. 2005 Oct;5(5):485-92. doi: 10.2174/156652305774329230.

6

Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice.在小鼠中，一种 chimpanzee 腺病毒载体的裂谷热疫苗的免疫原性和功效。

Virol J. 2013 Dec 5;10:349. doi: 10.1186/1743-422X-10-349.

7

Future Prospects for the Development of Cost-Effective Adenovirus Vaccines.开发具有成本效益的腺病毒疫苗的未来前景

Int J Mol Sci. 2017 Mar 23;18(4):686. doi: 10.3390/ijms18040686.

8

Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform.重组兽用疫苗的研发与注册。金丝雀痘病毒载体平台实例

Vaccine. 2007 Jul 26;25(30):5606-12. doi: 10.1016/j.vaccine.2006.11.066. Epub 2006 Dec 8.

9

A novel alphavirus replicon-vectored vaccine delivered by adenovirus induces sterile immunity against classical swine fever.一种新型甲型肝炎病毒复制子载体疫苗通过腺病毒传递可诱导对古典猪瘟的无菌免疫。

Vaccine. 2011 Oct 26;29(46):8364-72. doi: 10.1016/j.vaccine.2011.08.085. Epub 2011 Sep 5.

10

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.来自B和D亚组的六种罕见血清型重组腺病毒疫苗载体的比较血清阳性率和免疫原性。

J Virol. 2007 May;81(9):4654-63. doi: 10.1128/JVI.02696-06. Epub 2007 Feb 28.

引用本文的文献

1

Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil.ChAdOx1 nCoV-19（AZD1222）作为同源第四剂加强针的免疫原性和安全性：巴西3期COV003试验的一项子研究

Mayo Clin Proc Innov Qual Outcomes. 2025 Jul 11;9(4):100642. doi: 10.1016/j.mayocpiqo.2025.100642. eCollection 2025 Aug.

2

Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions.针对RNA病毒的疫苗策略：当前进展与未来方向

Vaccines (Basel). 2024 Nov 28;12(12):1345. doi: 10.3390/vaccines12121345.

3

Cancer vaccines: an update on recent achievements and prospects for cancer therapy.

本文引用的文献

1

Expert review on global real-world vaccine effectiveness against SARS-CoV-2.全球真实世界 SARS-CoV-2 疫苗有效性的专家评价

Expert Rev Vaccines. 2022 Sep;21(9):1255-1268. doi: 10.1080/14760584.2022.2092472. Epub 2022 Jun 30.

2

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination.接种AZD1222（ChAdOx1 nCoV-19）疫苗后血栓性血小板减少症（TTS）病例的地理分布。

Lancet Glob Health. 2022 Jan;10(1):e33-e34. doi: 10.1016/S2214-109X(21)00545-3.

3

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations.